Can infection with Clavispora lusitaniae cause an elevated serum (1→3)-β-D-glucan (Fungitell) result?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Clavispora lusitaniae Cause Elevated Fungitell Results?

Yes, Clavispora lusitaniae (formerly Candida lusitaniae) infection will cause elevated serum (1→3)-β-D-glucan (Fungitell) results, as this organism contains β-D-glucan in its cell wall like other Candida species.

Mechanism and Expected Results

  • β-D-glucan is a cell wall component of most pathogenic fungi, including all Candida species, and the Fungitell assay detects this polysaccharide when invasive fungal infection is present 1.

  • C. lusitaniae, being a Candida species, possesses (1→3)-β-D-glucan in its cell wall structure, making it detectable by the Fungitell assay just like C. albicans, C. glabrata, C. parapsilosis, and other Candida species 1.

  • In documented candidemia cases (including all Candida species), all culture-proven samples showed BDG values >80 pg/ml (mean 1247 pg/ml; range 116-2990 pg/ml) using the automated Fungitell assay 2.

Clinical Context for C. lusitaniae

  • C. lusitaniae is an emerging opportunistic pathogen that causes breakthrough fungemia in immunocompromised patients, particularly those with hematologic malignancies, bone marrow transplant recipients, and neutropenic patients 3.

  • This organism has characteristic resistance patterns, including documented amphotericin B resistance and rapid development of multidrug resistance during echinocandin therapy 4, 3.

  • C. lusitaniae can be confused with other fungal species such as C. tropicalis, C. parapsilosis, and even Saccharomyces cerevisiae due to morphologic similarities, making biomarker testing particularly valuable 5.

Diagnostic Performance Considerations

  • The Fungitell assay has a pooled sensitivity of 75-80% and specificity of approximately 80% for invasive fungal infections, with results available within 45 minutes to 24 hours 1, 6, 2.

  • The test cannot distinguish between different fungal species - a positive result indicates invasive fungal infection but does not differentiate C. lusitaniae from other Candida species, Aspergillus, Fusarium, or Pneumocystis jirovecii 7, 8.

  • Blood culture sensitivity for candidemia ranges from only 21-71%, so negative cultures do not rule out infection, making BDG testing a valuable adjunct 6.

Important Caveats

  • False-positive BDG results are common in ICU patients, those receiving hemodialysis, albumin or IVIG infusions, certain antibiotics (particularly amoxicillin-clavulanate, piperacillin-tazobactam), and those with mucositis or gastrointestinal mucosal disruption 1, 6, 8.

  • Requiring consecutive positive results rather than a single positive test improves specificity and reduces false-positive interpretation 1, 8.

  • A positive Fungitell result should prompt blood cultures, site-specific cultures, and consideration of empiric antifungal therapy in high-risk patients with clinical signs of infection 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Candida lusitaniae: a cause of breakthrough fungemia in cancer patients.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001

Guideline

Management of Elevated Fungitell Results

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Diagnosis and Management of Invasive Aspergillosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Diagnostic Accuracy of 1-3 Beta-D-Glucan for Pneumocystis jirovecii Pneumonia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.